Author:
Nam Joo-Hyun,Park Jeong-Yeol,Baek Min-Hyun,Han Ji-Hyun,Han Woo-Suk,Ko A-Ra
Reference103 articles.
1. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol. 2004;94:699–704.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505.
3. Banno K, Nogami Y, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Susumu N, Aoki D. Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer. Int J Mol Sci. 2013;14:12123–37.
4. Barbati A, Mariani L, Porpora MG, Anceschi M, Collini P, Lauro V, Cosmi EV. Serum evaluation of p53 protein in patients with gynaecological cancer. Anticancer Res. 2000;20(2A):1003–5.
5. Ben-Hur H, Berman V, Sandler B, Smimoff P, Gurevich P, Open M, Zusman I. Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: a comparative study. Eur J Gynaecol Oncol. 1997;18(5):400–6.